Enter inventor name

Michael L Vazquez

This inventor holds 131 USPTO granted patents, primarily in Retroviral Protease Inhibitors (CPC class C07D-). Top assignees: G.d. Searle & Company, G.d. Searle LLC, Monsanto Company. Active years: 1990-2012.

USPTO Granted Patents = 131

% Patents Active = 64.1

Average Co-Inventor Count = 6.8

ph-index = 18

Forward Citations = 1,123(Granted Patents)

Forward Citations (Not Self Cited) = 820(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Gurnee, MO (US) (2002)
Ballwin, MO (US) (1990 - 2008)
Gurnee, IL (US) (1993 - 2012)

Company Filing History:

97 out of 1,323

G.d. Searle & Company

Pharmacia Corporation

Monsanto Company of St. Louis

8. 6 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1990-2012

Loading Chart...

Areas of Expertise:

Retroviral Protease Inhibitors

Amino Acid Derivatives

Hydroxyethylamino Sulfonamides

Substituted Pyrazoles

Pyrazolyl Compounds

Sulfonamide Derivatives

p38 Kinase Inhibitors

Synthesis Methods

Inflammation Treatment

Bis-Amino Acid Compounds

Hydroxyethylamino Sulfonyl Urea

131 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE43802 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2012-11-12),

2. RE43596 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2012-08-20),

3. RE42889 - α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2011-10-31),

4. 7829564 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2010-11-09),

5. 7531538 - α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2009-05-12),

6. 7339078 - Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors (2008-03-04),

7. 7320983 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2008-01-22),

8. 7312333 - Retroviral protease inhibitors (2007-12-25),

9. 7232817 - α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2007-06-19),

10. 7211597 - Substituted pyrazolyl compounds for the treatment of inflammation (2007-05-01),

11. 7202258 - α- and β-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors (2007-04-10),

12. 7199158 - Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors (2007-04-03),

13. 7189864 - Method of preparing intermediates useful in synthesis of retroviral protease inhibitors (2007-03-13),

14. 7186743 - Substituted pyrazolyl compounds for the treatment of inflammation (2007-03-06),

15. 7161033 - Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors (2007-01-09),

Title: Michael L. Vazquez: A Pioneer in Retroviral Research

Introduction

Michael L. Vazquez is a prominent inventor based in Gurnee, Illinois, whose contributions to the field of retroviral protease inhibitors have garnered him an impressive total of 131 patents. His research and innovation have played a pivotal role in advancing medical science, particularly in the fight against HIV.

Latest Patents

Among his latest patents, Vazquez has developed α- and β-amino acid hydroxyethylamino sulfonamides, which are recognized for their efficacy as retroviral protease inhibitors. These compounds specifically target HIV protease, showing great potential in the treatment and management of HIV infections. The significance of these inventions lies in their ability to disrupt the viral lifecycle, providing a crucial tool in the ongoing battle against retroviral diseases.

Career Highlights

Throughout his career, Michael L. Vazquez has worked with G.D. Searle & Company and G.D. Searle LLC, renowned organizations that focus on pharmaceutical advancements. His tenure at these companies has allowed him to contribute significantly to innovative research in pharmacology, leading to numerous breakthroughs and patents.

Collaborations

Vazquez has collaborated with several notable individuals in his field, including Daniel P. Getman and Gary A. DeCrescenzo. These partnerships have facilitated the development of groundbreaking inventions, demonstrating the importance of teamwork and shared knowledge in the quest for medical advancements.

Conclusion

Michael L. Vazquez stands out as a leading inventor whose work has profoundly impacted the field of retroviral research. With a remarkable portfolio of patents, his contributions continue to inspire fellow researchers and pave the way for new innovations in the fight against HIV. His dedication to science exemplifies the vital role inventors play in improving health outcomes worldwide.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]